1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc.

CTMX
CytomX Therapeutics, Inc.US flagNASDAQ Global Select
3.36
USD
+0.01
- -
731.48MMarket Cap

Total Valuation

CytomX Therapeutics, Inc. carries a market capitalization of 731.48M, placing it among publicly traded companies globally. Its enterprise value stands at 492.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap731.48M
Enterprise Value492.55M

Share Statistics

CytomX Therapeutics, Inc. currently has 217.90M shares outstanding.

Shares Outstanding217.90M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

CytomX Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 10.85. The price-to-sales ratio is 38.33, and the price-to-book ratio stands at 2.71.

PE Ratio10.85
PS Ratio38.33
PB Ratio2.71
P/TBV Ratio2.72
P/FCF Ratio-8.52
P/OCF Ratio-8.51

Enterprise Valuation

The EV/Sales ratio of 26.91 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.71 provides insight into valuation relative to core operating earnings.

EV / Sales26.91
EV / EBITDA15.84
EV / EBIT16.71
EV / FCFN/A

Financial Position

CytomX Therapeutics, Inc. maintains a current ratio of 9.36, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.

Current Ratio9.36
Quick Ratio9.23
Debt / Equity1.89
Debt / EBITDA-0.07
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-37.75
Return on Assets (ROA)-28.64
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax231,000.00
Effective Tax RateN/A

Stock Price Statistics

CytomX Therapeutics, Inc.'s stock has gained approximately 75.91623% over the past 52 weeks. The 50-day moving average sits at 3.36, while the 200-day moving average is 4.18.

Beta (5Y)N/A
52-Week Price Change75.91623%
50-Day Moving Average3.36
200-Day Moving Average4.18
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, CytomX Therapeutics, Inc. generated 18.30M in revenue and converted that into -79.65M in net income, yielding earnings per share of -0.43. EBITDA reached -86.21M, while operating income came in at -87.15M.

Revenue18.30M
Gross ProfitN/A
Operating Income-87.15M
Pretax Income-79.42M
Net Income-79.65M
EBITDA-86.21M
EBIT-87.15M
Earnings Per Share (EPS)-0.43

Balance Sheet

CytomX Therapeutics, Inc. holds 330.28M in cash and equivalents against 5.70M in total debt, resulting in a net debt position of -17.22M. Total book value stands at 302.07M, with working capital of 333.29M providing operational flexibility.

Cash & Cash Equivalents330.28M
Total Debt5.70M
Net Debt-17.22M
Equity (Book Value)302.07M
Book Value Per Share1.39
Working Capital333.29M

Cash Flow

CytomX Therapeutics, Inc. produced -82.41M in operating cash flow over the past twelve months. After subtracting -74,000.00 in capital expenditures, free cash flow totaled -82.48M - equivalent to -0.44 per share.

Operating Cash Flow-82.41M
Capital Expenditures-74,000.00
Free Cash Flow-82.48M
FCF Per Share-0.44

Margins

CytomX Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -476.19 and net profit margin of -435.21 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-476.19
Pretax Margin-433.95
Profit Margin-435.21
EBITDA Margin-471.05

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-30.83
FCF Yield-11.74

Scores

CytomX Therapeutics, Inc. posts an Altman Z-Score of 3.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.77